Middlemen raise drug prices, limiting access to cheaper medicines

Patients are increasingly finding themselves in a decision‑making limbo, with neither the individual receiving care nor the treating physician taking the final call on treatment plans. A 2024 survey of 1,200 U.S. hospitals found that in 58 % of cases involving complex or high‑cost interventions, the ultimate decision was deferred to hospital committees or insurance reviewers, leaving both parties with little say. The study, published in *Health Affairs*, noted that this trend is driven partly by rising administrative costs and a growing emphasis on cost‑effectiveness metrics that override clinical judgment.

The lack of definitive decision‑makers has raised concerns among medical ethicists and patient advocacy groups. Dr. Maya Patel, a health policy researcher at Stanford University, explained that when neither patients nor clinicians are empowered to finalize care choices, treatment plans can become misaligned with patient values and clinical best practices. She cited examples where patients were offered a standard surgical procedure despite a strong preference for less invasive options, and where physicians, constrained by institutional guidelines, could not tailor treatments to individual circumstances. The study also highlighted that shared‑decision‑making initiatives, which have been promoted for years, are not being implemented consistently across specialties.

Healthcare leaders are responding by piloting new frameworks that aim to restore decision‑autonomy to both patients and doctors. Several hospitals have introduced “decision‑rights” committees that include patient representatives and independent clinicians to review cases where cost or policy pressures threaten individualized care. While the effectiveness of these models remains to be seen, the growing awareness of the problem signals a shift toward re‑centering the patient‑clinician partnership in medical decision‑making.